

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



利君國際醫藥(控股)有限公司

Lijun International Pharmaceutical (Holding) Co., Ltd.

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2005)

ANNOUNCEMENT OF TURNOVER AND GROSS PROFIT INFORMATION FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2010

The Company is pleased to announce its financial information of turnover and gross profit, which has not been reviewed by its auditors, for the nine months ended 30 September 2010.

The board of directors (the “Board”) of Lijun International Pharmaceutical (Holding) Co., Ltd. (the “Company”) is pleased to announce the preliminary financial information of turnover and gross profit of the Company and its subsidiaries (together, the “Group”) for the nine months ended 30 September 2010 based on its management accounts which have not been reviewed by the auditors.

Total turnover of the Group, which has not been reviewed by the auditors, for the nine months ended 30 September 2010 increased by approximately 12.5% as compared with the same period of 2009 to approximately HK\$1,407 million, with gross profit of 50.0% (For the nine months ended 30 September 2009: 49.6%) and in particular:

- Turnover for the nine months ended 30 September 2010 of intravenous infusion solution increased by approximately 16.9% as compared to the same period of 2009 to approximately HK\$562 million, with gross profit of 49.1% (For the nine months ended 30 September 2009: 47.7%). Among which, sales of Non-PVC Soft Bag infusion

solution was HK\$172 million, representing 33.1% of the total sales of intravenous infusion solution and an increase of 54.2% as compared with the same period of 2009; sales of PP Plastic Bottle infusion solution was HK\$221 million, representing 42.5% of the total sales of intravenous infusion solution and an increase of 6.6% as compared with the same period of 2009; and

- Turnover for the nine months ended 30 September 2010 of antibiotics and non-antibiotics increased by approximately 9.8% as compared to the same period of 2009 to approximately HK\$845 million, with gross profit of 50.5% (For the nine months ended 30 September 2009: 50.7%). Among which, sales of Lijunsha increased by 6.9% to HK\$319 million; sales of Paiqi increased by 11.8% to HK\$91 million; sales of Dobesilate increased by 14.4% to HK\$56 million; sales of Lixiding increased by 35.3% to HK\$26 million.

In terms of business segments, intravenous infusion solution, antibiotics and non-antibiotics accounted for approximately 40.0%, 38.2% and 21.8% of total turnover for the nine months ended 30 September 2010 which has not been reviewed by the auditors (For the nine months ended 30 September 2009: 38.5%, 38.9% and 22.6%).

Shareholders and investors are advised to exercise caution in dealing in the shares of the Company.

On behalf of the Board
Sze Wing Kin, Pierre
Company Secretary

Hong Kong, 29 October 2010

As at the date of this announcement, the Board comprises Mr. Wu Qin, Mr. Qu Jiguang, Mr. Xie Yunfeng, Mr. Huang Chao, Ms. Sun Xinglai, Mr. Wang Xian Jun, Mr. Duan Wei, Ms. Zhang Guifu, Mr. Bao Leyuan and Ms. Gao Shuping as executive Directors, Mr. Liu Zhiyong as non-executive Director, and Mr. Wang Yibing, Mr. Leung Chong Shun and Mr. Chow Kwok Wai as independent non-executive Directors.